3:51 PM
 | 
Jun 11, 2018
 |  BC Extra  |  Company News

Alexion partners with Complement, divests non-core asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced a pair of deals on Monday, including a deal with Complement Pharma (Amsterdam, The Netherlands) to develop a preclinical complement 6 (C6) inhibitor for neurodegenerative diseases. The biotech also divested ALXN1101 to a newly formed subsidiary of BridgeBio Pharma LLC (Palo Alto, Calif.).

Alexion and Complement will co-develop Complement's CP010, a humanized mAb C6 complement inhibitor, through Phase Ib development. Complement...

Read the full 308 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >